BRAF and melanoma: PEGylated cationic liposomes conjugated to AS1411 aptamer (AS1411-PEG-liposome, designated as ASLP) and equipped with anti-BRAF siRNA (siBraf) can might be utilized as a tumor-targeting gene-silencing delivery system (ASLP/siBraf) against melanomas since they can exhibit significant silencing activity against the BRAF gene and inhibit melanoma growth [102].